- Conditions
- Non Alcoholic Steatohepatitis (NASH)
- Interventions
- Tropifexor, Licogliflozin, Placebo
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 28
- States / cities
- Dothan, Alabama • Coronado, California • Los Angeles, California + 23 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Urinary Urge Incontinence
- Interventions
- Oxybutynin extended release, Posterior Tibial Nerve Stimulation, Placebo
- Drug · Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Raleigh, North Carolina
- Conditions
- mCRPC
- Interventions
- Talazoparib with enzalutamide, Placebo with enzalutamide
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,054 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 132
- States / cities
- Anchorage, Alaska • Chandler, Arizona • Gilbert, Arizona + 93 more
- Conditions
- Hepatitis B
- Interventions
- TDF, FTC/TDF, TDF Placebo, FTC/TDF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 3
- States / cities
- Bradenton, Florida • Flushing, New York • Philadelphia, Pennsylvania
- Conditions
- Cancer, Hepatocellular
- Interventions
- nivolumab, ipilimumab, TACE
- Drug · Procedure
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 5
- States / cities
- Coronado, California • Washington D.C., District of Columbia • Louisville, Kentucky + 1 more
- Conditions
- Insomnia, Malignant Solid Neoplasm
- Interventions
- Biospecimen Collection, Placebo Administration, Single Agent Therapy
- Procedure · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 25 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- CJC-1134-PC Injection, Weekly placebo for CJC-1134-PC Injection
- Drug
- Lead sponsor
- ConjuChem
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Inglewood, California • Tarzana, California + 16 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Treprostinil Diolamine, Placebo
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 690 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fresno, California + 33 more
- Conditions
- Psoriatic Arthritis
- Interventions
- Etanercept, Methotrexate, Placebo to Etanercept, Placebo to Methotrexate
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 851 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 55
- States / cities
- Tuscaloosa, Alabama • Glendale, Arizona • Mesa, Arizona + 50 more
- Conditions
- Chronic Gastrointestinal Graft vs Host Disease
- Interventions
- orBec, Placebo
- Drug
- Lead sponsor
- Soligenix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- Hackensack, New Jersey • Buffalo, New York • Nashville, Tennessee
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- CS-917, metformin hydrochloride, pioglitazone
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Northport, Alabama • Mesa, Arizona + 62 more
- Conditions
- Multiple Sclerosis
- Interventions
- metformin, Placebo
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 55 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- HIV Infections
- Interventions
- VH4004280, VH4011499, VH4004280 Matching Placebo, VH4011499 Matching Placebo, Antiretroviral therapy
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Bakersfield, California • DeLand, Florida • Newark, New Jersey
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Placebo, Sotatercept, SOC
- Drug · Other
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 7 more
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension
- Interventions
- Sitaxsentan, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 32
- States / cities
- Fountain Valley, California • Mather, California • Sacramento, California + 28 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Durvalumab, Bevacizumab, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 150 Years
- Enrollment
- 908 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 31 more
- Conditions
- HIV Infections
- Interventions
- GW695634
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Fountain Valley, California • San Francisco, California + 15 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- rivoglitazone HCl, placebo, pioglitazone HCl, pioglitazone HCl 45 mg, metformin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 18
- States / cities
- Huntsville, Alabama • San Diego, California • San Francisco, California + 14 more
- Conditions
- Influenza A
- Interventions
- VX-787 300 mg, VX-787 600 mg, Oseltamivir 75 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 129
- States / cities
- Athens, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 126 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg), Aclidinium bromide 400 μg (AB 400 μg), Formoterol fumarate 12 μg (FF 12 μg), Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg, Tiotropium 18 μg (TIO 18 μg), Placebo to TIO 18 μg
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 130 Years
- Enrollment
- 1,595 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 85
- States / cities
- Gulf Shores, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- Roniciclib (BAY1000394), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 7
- States / cities
- Boca Raton, Florida • Port Saint Lucie, Florida • St Louis, Missouri + 4 more
- Conditions
- Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Depression
- Interventions
- TNX-102 SL, Placebo sublingual tablet
- Drug
- Lead sponsor
- Tonix Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Buena Park, California • Chino, California + 24 more
- Conditions
- Locally Advanced Cervical Cancer
- Interventions
- Durvalumab, Cisplatin, Carboplatin, external beam radiation therapy (EBRT) + brachytherapy
- Biological · Drug · Radiation
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Female only
- Enrollment
- 770 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • La Jolla, California • Orange, California + 10 more
- Conditions
- Macular Degeneration, Choroidal Neovascularization
- Interventions
- Verteporfin Photodynamic Therapy, Ranibizumab, Verteporfin Placebo, Ranibizumab Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 36
- States / cities
- Tucson, Arizona • Beverly Hills, California • Oakland, California + 33 more